BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

21 related articles for article (PubMed ID: 8905035)

  • 1. Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients.
    Barlesi F; Imbs DC; Tomasini P; Greillier L; Galloux M; Testot-Ferry A; Garcia M; Elharrar X; Pelletier A; André N; Mascaux C; Lacarelle B; Cheikh RE; Serre R; Ciccolini J; Barbolosi D
    Oncotarget; 2017 Jul; 8(29):47161-47166. PubMed ID: 28525370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC).
    Baldini E; Ardizzoni A; Prochilo T; Cafferata MA; Boni L; Tibaldi C; Neumaier C; Conte PF; Rosso R;
    Br J Cancer; 2001 Nov; 85(10):1452-5. PubMed ID: 11720427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP).
    Baldini E; Tibaldi C; Ardizzoni A; Salvati F; Antilli A; Portalone L; Barbera S; Romano F; De Marinis F; Migliorino MR; Noseda MA; Borghini U; Crippa M; Ferrara G; Raimondi M; Fioretti M; Bandera M; Pennucci MC; Galeasso G; Cacciani GC; Lepidini G; Sunseri G; Lanfranco C; Rinaldi M; Rosso R
    Br J Cancer; 1998 Jun; 77(12):2367-70. PubMed ID: 9649160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
    Souquet PJ; Fournel P; Bohas CH; Fortune IC; Chatte G
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):8-10. PubMed ID: 8610239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination chemotherapy with vinorelbine, ifosfamide, and cisplatin: a phase II study in stage IIIB-IV non-small cell lung cancer.
    Baldini E; Tibaldi C; Chella A; Angeletti CA; Romanini A; Andrei A; Algeri R; Silvano G; Conte PF
    Semin Oncol; 1994 Jun; 21(3 Suppl 4):12-5. PubMed ID: 8209271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer.
    Masters GA; Mauer AM; Hoffman PC; Wyka D; Samuels BL; Krauss SA; Watson S; Golomb H; Vokes EE
    Ann Oncol; 1998 Jun; 9(6):677-80. PubMed ID: 9681085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vinorelbine, ifosfamide, and cisplatin combination as salvage chemotherapy in advanced non-small cell lung cancer.
    Song SY; Kim WS; Kim K; Jung CW; Im YH; Kim HJ; Kang WK; Lee HG; Kwon OJ; Rhee CH; Park CH; Park K
    Jpn J Clin Oncol; 2003 Oct; 33(10):509-13. PubMed ID: 14623918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study with cisplatin, ifosfamide and weekly administration of vinorelbine as an outpatient combination chemotherapy for advanced non small cell lung cancer.
    Tibaldi C; Baldini E; Ricci S; Conte PF
    Anticancer Res; 1996; 16(5B):3213-5. PubMed ID: 8920792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine, ifosfamide and Navelbine (GIN): a platinum-free combination in advanced non-small-cell lung cancer (NSCLC).
    Baldini E; Ardizzoni A; Prochilo T; Cafferata MA; Boni L; Tibaldi C
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S25-8. PubMed ID: 12042986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinorelbine (Navelbine) in the treatment of non-small-cell lung cancer: studies with single-agent therapy and in combination with cisplatin.
    Gralla R; Harper P; Johnson S; Delgado FM
    Ann Oncol; 1999; 10 Suppl 5():S41-5. PubMed ID: 10582138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer.
    Baldini E; Tibaldi C; Chella A; Angeletti CA; Silvano G; Andrei A; Algeri R; Conte PF
    Ann Oncol; 1996 Sep; 7(7):747-9. PubMed ID: 8905035
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.